目的:基于PI3K/AKT/mTOR信号通路探讨人参皂苷CK对Aβ42活化小胶质(BV2)细胞抗炎及Aβ寡聚体吞噬作用机制。方法:利用10μm o l/L Aβ42寡聚体作用BV2细胞建立小胶质细胞活化模型,通过细胞实时监测系统观察人参皂苷CK对BV2细胞活力的影...目的:基于PI3K/AKT/mTOR信号通路探讨人参皂苷CK对Aβ42活化小胶质(BV2)细胞抗炎及Aβ寡聚体吞噬作用机制。方法:利用10μm o l/L Aβ42寡聚体作用BV2细胞建立小胶质细胞活化模型,通过细胞实时监测系统观察人参皂苷CK对BV2细胞活力的影响;利用免疫荧光技术检测人参皂苷CK对BV2细胞介导Aβ吞噬能力,以及对BV2细胞不同表型标志物CD68、CD206蛋白的调控能力;通过ELISA技术测定人参皂苷CK对BV2细胞外Aβ42表达量的影响以及对炎症因子IL-4、IL-6分泌的调控水平;利用Western Blotting技术检测人参皂苷CK对BV2细胞内PI3K/A K T/m T OR信号通路相关蛋白表达的调控能力。结果:与空白组比较,模型组BV2细胞信号值降低,BV2细胞内Aβ42荧光表达强度显著减少(P<0.05),BV2细胞外Aβ42蛋白含量显著增多(P<0.05),BV2细胞内CD68的表达水平显著增加(P<0.05),CD206的表达水平显著降低(P<0.05),BV2细胞IL-4分泌水平显著降低(P<0.05),IL-6分泌水平显著升高(P<0.05);与模型组比较,不同剂量人参皂苷CK作用后,BV2细胞信号值升高,BV2细胞Aβ荧光表达强度显著增加(P<0.05),BV2细胞外Aβ蛋白含量显著降低(P<0.05),BV2细胞内CD68表达水平显著降低(P<0.05),CD206表达水平显著增加(P<0.05),BV2细胞IL-4分泌水平显著升高(P<0.05),IL-6分泌水平显著降低(P<0.05)。结论:人参皂苷CK通过PI3K/AKT/mTOR信号通路,增加BV2细胞对Aβ的吞噬能力,促进活化BV2细胞由M1表型向M2表型极化能力,抑制炎症反应的产生。展开更多
Gambogic acid(GA) is an anticancer agent in phase Ⅱb clinical trial in China but its mechanism of action has not been fully clarified. The present study was designed to search the possible target-related proteins of ...Gambogic acid(GA) is an anticancer agent in phase Ⅱb clinical trial in China but its mechanism of action has not been fully clarified. The present study was designed to search the possible target-related proteins of GA in cancer cells using proteomic method and establish possible network using bioinformatic analysis. Cytotoxicity and anti-migration effects of GA in MDA-MB-231 cells were checked using MTT assay, flow cytometry, wound migration assay, and chamber migration assay. Possible target-related proteins of GA at early(3 h) and late stage(24 h) of treatment were searched using a proteomic technology, two-dimensional electrophoresis(2-DE). The possible network of GA was established using bioinformatic analysis. The intracellular expression levels of vimentin, keratin 18, and calumenin were determined using Western blotting. GA inhibited cell proliferation and induced cell cycle arrest at G2/M phase and apoptosis in MDA-MB-231 cells. Additionally, GA exhibited anti-migration effects at non-toxic doses. In 2-DE analysis, totally 23 possible GA targeted proteins were found, including those with functions in cytoskeleton and transport, regulation of redox state, metabolism, ubiquitin-proteasome system, transcription and translation, protein transport and modification, and cytokine. Network analysis of these proteins suggested that cytoskeleton-related proteins might play important roles in the effects of GA. Results of Western blotting confirmed the cleavage of vimentin, increase in keratin 18, and decrease in calumenin levels in GA-treated cells. In summary, GA is a multi-target compound and its anti-cancer effects may be based on several target-related proteins such as cytoskeleton-related proteins.展开更多
文摘目的:基于PI3K/AKT/mTOR信号通路探讨人参皂苷CK对Aβ42活化小胶质(BV2)细胞抗炎及Aβ寡聚体吞噬作用机制。方法:利用10μm o l/L Aβ42寡聚体作用BV2细胞建立小胶质细胞活化模型,通过细胞实时监测系统观察人参皂苷CK对BV2细胞活力的影响;利用免疫荧光技术检测人参皂苷CK对BV2细胞介导Aβ吞噬能力,以及对BV2细胞不同表型标志物CD68、CD206蛋白的调控能力;通过ELISA技术测定人参皂苷CK对BV2细胞外Aβ42表达量的影响以及对炎症因子IL-4、IL-6分泌的调控水平;利用Western Blotting技术检测人参皂苷CK对BV2细胞内PI3K/A K T/m T OR信号通路相关蛋白表达的调控能力。结果:与空白组比较,模型组BV2细胞信号值降低,BV2细胞内Aβ42荧光表达强度显著减少(P<0.05),BV2细胞外Aβ42蛋白含量显著增多(P<0.05),BV2细胞内CD68的表达水平显著增加(P<0.05),CD206的表达水平显著降低(P<0.05),BV2细胞IL-4分泌水平显著降低(P<0.05),IL-6分泌水平显著升高(P<0.05);与模型组比较,不同剂量人参皂苷CK作用后,BV2细胞信号值升高,BV2细胞Aβ荧光表达强度显著增加(P<0.05),BV2细胞外Aβ蛋白含量显著降低(P<0.05),BV2细胞内CD68表达水平显著降低(P<0.05),CD206表达水平显著增加(P<0.05),BV2细胞IL-4分泌水平显著升高(P<0.05),IL-6分泌水平显著降低(P<0.05)。结论:人参皂苷CK通过PI3K/AKT/mTOR信号通路,增加BV2细胞对Aβ的吞噬能力,促进活化BV2细胞由M1表型向M2表型极化能力,抑制炎症反应的产生。
基金supported by the grants from National Science&Technology Major Project"Key New Drug Creation and Manufacturing Program",China(Nos.2009ZX09308-005,2009ZX09311-001,2009ZX09502-020,2009ZX09304-002)Major Projects of Knowledge InnovationProgram of the Chinese Academy of Sciences(No.KSCX2-YW-R-166)~~
基金supported by the Twelfth Five-Year National Science & Technology Support Program(No.2012BAI 29B06)Shanghai Science & Technology Support Program(No.13431900 401)+4 种基金China Postdoctoral Science Foundation Funded Project(No.2012M5 10907)Shanghai Postdoctoral Scientific Program(No.13R21417800)the Postdoctor Research Program of Shanghai Institutes for Biological Sciences,Chinese Academy of Sciences(No.2012KIP516)the Sanofi-Aventis-Shanghai Institutes for Biological Sciences Scholarship Programthe National Nature Science Foundation(Nos.81302809 and 81373964)
文摘Gambogic acid(GA) is an anticancer agent in phase Ⅱb clinical trial in China but its mechanism of action has not been fully clarified. The present study was designed to search the possible target-related proteins of GA in cancer cells using proteomic method and establish possible network using bioinformatic analysis. Cytotoxicity and anti-migration effects of GA in MDA-MB-231 cells were checked using MTT assay, flow cytometry, wound migration assay, and chamber migration assay. Possible target-related proteins of GA at early(3 h) and late stage(24 h) of treatment were searched using a proteomic technology, two-dimensional electrophoresis(2-DE). The possible network of GA was established using bioinformatic analysis. The intracellular expression levels of vimentin, keratin 18, and calumenin were determined using Western blotting. GA inhibited cell proliferation and induced cell cycle arrest at G2/M phase and apoptosis in MDA-MB-231 cells. Additionally, GA exhibited anti-migration effects at non-toxic doses. In 2-DE analysis, totally 23 possible GA targeted proteins were found, including those with functions in cytoskeleton and transport, regulation of redox state, metabolism, ubiquitin-proteasome system, transcription and translation, protein transport and modification, and cytokine. Network analysis of these proteins suggested that cytoskeleton-related proteins might play important roles in the effects of GA. Results of Western blotting confirmed the cleavage of vimentin, increase in keratin 18, and decrease in calumenin levels in GA-treated cells. In summary, GA is a multi-target compound and its anti-cancer effects may be based on several target-related proteins such as cytoskeleton-related proteins.